CytomX Therapeutics (CTMX) Competitors

CytomX Therapeutics logo
$1.96 -0.03 (-1.51%)
As of 11:44 AM Eastern
This is a fair market value price provided by Massive. Learn more.

CTMX vs. SRPT, VIR, REPL, AGIO, and MESO

Should you buy CytomX Therapeutics stock or one of its competitors? CytomX Therapeutics's main competitors and comparable companies include Sarepta Therapeutics (SRPT), Vir Biotechnology (VIR), Replimune Group (REPL), Agios Pharmaceuticals (AGIO), and Mesoblast (MESO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does CytomX Therapeutics compare to Sarepta Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Sarepta Therapeutics (NASDAQ:SRPT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

CytomX Therapeutics presently has a consensus target price of $12.10, indicating a potential upside of 506.52%. Sarepta Therapeutics has a consensus target price of $23.67, indicating a potential upside of 60.04%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe CytomX Therapeutics is more favorable than Sarepta Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CytomX Therapeutics
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.83
Sarepta Therapeutics
6 Sell rating(s)
6 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.00

CytomX Therapeutics has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CytomX Therapeutics$14.03M31.00-$17.37M-$0.50N/A
Sarepta Therapeutics$2.20B0.72-$713.41M-$1.37N/A

Sarepta Therapeutics has a net margin of -5.86% compared to CytomX Therapeutics' net margin of -608.98%. Sarepta Therapeutics' return on equity of -0.20% beat CytomX Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CytomX Therapeutics-608.98% -33.97% -27.19%
Sarepta Therapeutics -5.86%-0.20%-0.09%

CytomX Therapeutics has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market.

In the previous week, CytomX Therapeutics had 3 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 7 mentions for CytomX Therapeutics and 4 mentions for Sarepta Therapeutics. CytomX Therapeutics' average media sentiment score of 0.65 beat Sarepta Therapeutics' score of 0.54 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CytomX Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Sarepta Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

67.8% of CytomX Therapeutics shares are held by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are held by institutional investors. 3.8% of CytomX Therapeutics shares are held by insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

CytomX Therapeutics beats Sarepta Therapeutics on 11 of the 17 factors compared between the two stocks.

How does CytomX Therapeutics compare to Vir Biotechnology?

Vir Biotechnology (NASDAQ:VIR) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 2.9% of Vir Biotechnology shares are held by insiders. Comparatively, 3.8% of CytomX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

CytomX Therapeutics has lower revenue, but higher earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vir Biotechnology$68.56M22.90-$437.99M-$1.26N/A
CytomX Therapeutics$14.03M31.00-$17.37M-$0.50N/A

In the previous week, Vir Biotechnology had 25 more articles in the media than CytomX Therapeutics. MarketBeat recorded 32 mentions for Vir Biotechnology and 7 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 0.65 beat Vir Biotechnology's score of 0.60 indicating that CytomX Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vir Biotechnology
4 Very Positive mention(s)
6 Positive mention(s)
12 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
CytomX Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Vir Biotechnology has a beta of 1.7, meaning that its share price is 70% more volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the broader market.

Vir Biotechnology presently has a consensus target price of $22.57, indicating a potential upside of 146.28%. CytomX Therapeutics has a consensus target price of $12.10, indicating a potential upside of 506.52%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CytomX Therapeutics is more favorable than Vir Biotechnology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vir Biotechnology
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78
CytomX Therapeutics
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.83

Vir Biotechnology has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -608.98%. Vir Biotechnology's return on equity of -21.38% beat CytomX Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Vir BiotechnologyN/A -21.38% -16.97%
CytomX Therapeutics -608.98%-33.97%-27.19%

Summary

CytomX Therapeutics beats Vir Biotechnology on 11 of the 16 factors compared between the two stocks.

How does CytomX Therapeutics compare to Replimune Group?

CytomX Therapeutics (NASDAQ:CTMX) and Replimune Group (NASDAQ:REPL) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

CytomX Therapeutics has a beta of 2.23, suggesting that its share price is 123% more volatile than the broader market. Comparatively, Replimune Group has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

Replimune Group has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -608.98%. CytomX Therapeutics' return on equity of -33.97% beat Replimune Group's return on equity.

Company Net Margins Return on Equity Return on Assets
CytomX Therapeutics-608.98% -33.97% -27.19%
Replimune Group N/A -157.78%-83.89%

CytomX Therapeutics presently has a consensus price target of $12.10, suggesting a potential upside of 506.52%. Replimune Group has a consensus price target of $18.17, suggesting a potential downside of 11.55%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CytomX Therapeutics is more favorable than Replimune Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CytomX Therapeutics
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.83
Replimune Group
2 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.50

CytomX Therapeutics has higher revenue and earnings than Replimune Group. Replimune Group is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CytomX Therapeutics$14.03M31.00-$17.37M-$0.50N/A
Replimune GroupN/AN/A-$313.94M-$2.79N/A

In the previous week, Replimune Group had 3 more articles in the media than CytomX Therapeutics. MarketBeat recorded 10 mentions for Replimune Group and 7 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 0.65 beat Replimune Group's score of 0.50 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CytomX Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Replimune Group
2 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 3.8% of CytomX Therapeutics shares are owned by company insiders. Comparatively, 5.4% of Replimune Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

CytomX Therapeutics beats Replimune Group on 12 of the 16 factors compared between the two stocks.

How does CytomX Therapeutics compare to Agios Pharmaceuticals?

CytomX Therapeutics (NASDAQ:CTMX) and Agios Pharmaceuticals (NASDAQ:AGIO) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

Agios Pharmaceuticals has a net margin of -264.76% compared to CytomX Therapeutics' net margin of -608.98%. CytomX Therapeutics' return on equity of -33.97% beat Agios Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
CytomX Therapeutics-608.98% -33.97% -27.19%
Agios Pharmaceuticals -264.76%-34.63%-32.04%

CytomX Therapeutics currently has a consensus price target of $12.10, suggesting a potential upside of 506.52%. Agios Pharmaceuticals has a consensus price target of $42.13, suggesting a potential upside of 42.85%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe CytomX Therapeutics is more favorable than Agios Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CytomX Therapeutics
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.83
Agios Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.60

In the previous week, Agios Pharmaceuticals had 1 more articles in the media than CytomX Therapeutics. MarketBeat recorded 8 mentions for Agios Pharmaceuticals and 7 mentions for CytomX Therapeutics. Agios Pharmaceuticals' average media sentiment score of 0.75 beat CytomX Therapeutics' score of 0.65 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CytomX Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Agios Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

CytomX Therapeutics has higher earnings, but lower revenue than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CytomX Therapeutics$14.03M31.00-$17.37M-$0.50N/A
Agios Pharmaceuticals$54.03M32.64-$412.78M-$6.32N/A

67.8% of CytomX Therapeutics shares are held by institutional investors. 3.8% of CytomX Therapeutics shares are held by company insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

CytomX Therapeutics has a beta of 2.23, suggesting that its share price is 123% more volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market.

Summary

CytomX Therapeutics beats Agios Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does CytomX Therapeutics compare to Mesoblast?

Mesoblast (NASDAQ:MESO) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

1.4% of Mesoblast shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 18.8% of Mesoblast shares are held by company insiders. Comparatively, 3.8% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Mesoblast has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -608.98%. Mesoblast's return on equity of 0.00% beat CytomX Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
MesoblastN/A N/A N/A
CytomX Therapeutics -608.98%-33.97%-27.19%

CytomX Therapeutics has lower revenue, but higher earnings than Mesoblast.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mesoblast$120.25M12.88-$57.50MN/AN/A
CytomX Therapeutics$14.03M31.00-$17.37M-$0.50N/A

Mesoblast presently has a consensus target price of $39.00, suggesting a potential upside of 227.73%. CytomX Therapeutics has a consensus target price of $12.10, suggesting a potential upside of 506.52%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CytomX Therapeutics is more favorable than Mesoblast.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mesoblast
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
CytomX Therapeutics
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.83

Mesoblast has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.23, meaning that its stock price is 123% more volatile than the broader market.

In the previous week, Mesoblast had 2 more articles in the media than CytomX Therapeutics. MarketBeat recorded 9 mentions for Mesoblast and 7 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 0.65 beat Mesoblast's score of -0.03 indicating that CytomX Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mesoblast
0 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral
CytomX Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

CytomX Therapeutics beats Mesoblast on 9 of the 15 factors compared between the two stocks.

Get CytomX Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CTMX vs. The Competition

MetricCytomX TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$426.20M$4.03B$7.76B$11.52B
Dividend YieldN/A3.62%2.46%4.42%
P/E Ratio-3.9123.8834.2129.69
Price / Sales30.3816.208.475.59
Price / CashN/A26.3721.9322.50
Price / Book1.494.084.303.66
Net Income-$17.37M-$22.88M$3.52B$392.29M
7 Day Performance-1.26%-7.26%-5.29%-4.21%
1 Month Performance-14.25%-6.09%-4.26%-6.68%
1 Year Performance-44.93%-6.92%-1.48%-7.19%

CytomX Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CTMX
CytomX Therapeutics
2.0616 of 5 stars
$1.96
-1.5%
$12.10
+518.9%
-48.7%$426.20M$14.03MN/A69
SRPT
Sarepta Therapeutics
3.5181 of 5 stars
$17.24
-3.3%
$23.67
+37.3%
-19.6%$2.01B$2.20BN/A835
VIR
Vir Biotechnology
2.3836 of 5 stars
$13.65
+11.8%
$22.14
+62.2%
+70.2%$1.99B$68.56MN/A367
REPL
Replimune Group
1.5383 of 5 stars
$22.26
+3.0%
$14.33
-35.6%
+138.2%$1.96BN/AN/A465
AGIO
Agios Pharmaceuticals
3.6261 of 5 stars
$31.38
+6.7%
$42.13
+34.2%
-30.9%$1.87B$54.03MN/A540

Related Companies and Tools


This page (NASDAQ:CTMX) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners